Aptar CSP Technologies brings Activ-Vial production to China for diabetes patients
20 Apr 2022 --- Aptar CSP Technologies is introducing local production of its Activ-Vial blood glucose test strip protection to diabetes patients in the China region. Activ-Vial will be produced at the company’s facility in Guangzhou, providing a best-in-class offering for the country’s growing diagnostics market, particularly for patients with diabetes conditions where blood glucose monitoring is a critical component of care.
By locally manufacturing Activ-Vial, Aptar CSP Technologies will bring production closer to the local customer, mitigating supply chain disruptions and, more importantly, providing an optimal solution to the local diabetes patient.
The move is a key component of the company’s strategic effort to significantly expand its market presence in China.
“This latest investment in local production expansion reflects our continued commitment to serving the China market,” comments Badre Hammond, VP of global commercial operations at Aptar CSP Technologies.
“This initiative not only represents an investment in the markets and communities we serve but allows us to leverage local supply chains, improving our cost structure and the [environmental] sustainability of operations.”
Polymer technology
The Activ-Vial solution features the company’s proprietary 3-Phase Activ-Polymer platform technology fully integrated into the vial, creating a microclimate that protects against moisture and other environmental conditions that can impact diabetes test strip stability.
Aptar’s Activ-Vial portfolio consists of 3-Phase Activ-Polymer flip-top vials and bottles.
Unlike traditional packaging options, this technology co-molds highly-engineered active particles into the vial, completely surrounding the product to scavenge moisture before it reaches the contents inside.
Additionally, the company’s patented “close in the mold” technology ensures a moisture-tight seal that maintains its integrity throughout shelf life and patient use life to deliver greater product stability.
Commercial launch
cGMP produced Activ-Vial products are now available on-site in Guangzhou for stability testing and readiness for commercial launch.
Aptar CSP Technologies, part of AptarGroup is a leader in active material science solutions to ensure product protection, extend shelf life and improve the patient experience.
In other developments, Aptar Group recently received approval from the US Food and Drug Administration for its patented Cartridge Pump System as a nasal delivery system for dry eye syndrome.
Also, Aptar Food and Beverage passed the American Society for Testing & Materials and International Safe Transit Association 3A testing procedures for its SeaWell active packaging system, confirming its robustness for e-commerce seafood delivery.
Edited by Joshua Poole
